DR. MAUREEN MURPHY

- Deputy Director, Ellen and Ronald Caplan Cancer Center, The Wistar Institute
- Ira Brand Professor
- Program Leader, Molecular and Cellular Oncogenesis Center
- Associate Vice President for Faculty Affairs

EDUCATION

- B.S., Biochemistry, Rutgers University
- Ph.D., Molecular Biology, University of Pennsylvania

CAREER HIGHLIGHTS

- Dr. Murphy studies the p53 tumor suppressor protein, focusing on the genetic variants of p53 that exist in populations of African descent and Ashkenazi Jewish descent.
- She works to identify hypomorphs of p53 certain mutations in the gene that make p53 less effective.
- By identifying cancer-causing p53 hypomorphs, Dr.
 Murphy then works to find drug treatments that restore p53's function in those cancer-causing hypomorphs.
- P53 varies broadly from person to person; humans can have a wide array of p53 hypomorphs, or mutations, several of which have been implicated in cancer.
- Dr. Murphy works with Dr. Andrew Kossenkov to use machine learning to develop a gene expression signature that will tell doctors whether patients have normal p53 or impaired p53 with an increased cancer risk.
- She hopes to develop a simple blood test for the 4.5M people in the U.S. with family histories of cancer.
- Began postdoctoral research at Princeton University in the laboratory of Dr. Arnold J. Levine, the co-discoverer of p53.

CONTACT

Darien Sutton

Director, Media Relations, Communications & Marketing dsutton@wistar.org
C: 215.870.2048 | O: 215.898.3988

The Wistar Institute

3601 Spruce Street | Philadelphia 19104 wistar.org





AVAILABLE FOR MEDIA INTERVIEWS ON

- Cutting-edge cancer research, particularly as it impacts populations of African descent and Ashkenazi Jewish Americans
- Encouraging young women to pursue STEM careers
- Utilizing personalized medicine approaches to cancer research

A SAMPLE OF DR. MURPHY'S MEDIA APPEARANCES

- Named and profiled as 2024 Woman of Influence, *Philadelphia Business Journal*, October 2024
- Key Mechanism Related to p53 Tumor Suppression Uncovered, Genetic Engineering and Biotechnology News, May 2023
- New p53 Function Signature Could Predict Cancer Risk, Inside Precision Medicine, February 2023

VISIT DR, MURPHY'S WIKIPEDIA
VISIT DR, MURPHY'S LINKEDIN